WFH NETWORK

Article on the WFH Gene Therapy Registry published

The WFH Gene Therapy Registry (GTR) is a global effort to ensure that safety and efficacy outcomes, as well as patient-important outcomes, are collected over the long-term on all patients with hemophilia who receive gene therapy. The core data set used as the basis for data collection in the WFH GTR was developed by a multi-stakeholder steering committee and has been published as a communication from the SSC of the ISTH (International Society of Thrombosis and Hemostasis Scientific and Standardization Committee), in the Journal of Thrombosis and Haemostasis (JTH).

This important manuscript details the development of the WFH Gene Therapy Registry, including the data fields that are important to collect on all patients with hemophilia who receive gene therapy.

To read Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: Communication from the SSC of the ISTH, please click here.